Last updated on September 2020

Low Dose Naltrexone for Chronic Pain From Arthritis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: PSORIATIC ARTHRITIS | Osteoarthritis | Rheumatoid Arthritis
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Patients must meet all of the following criteria in order to be eligible for enrollment:

  • Veteran or otherwise eligible for VA benefits, able to travel to VA Boston
  • One or more of the following chronic conditions:
  • osteoarthritis
  • rheumatoid arthritis
  • non-axial spondyloarthritis
  • Average daily pain interference with function (average of the 7 parts of question 9 on the Brief Pain Inventory) rated at least 4 on a scale of 0-10, and no higher than 9
  • No change in medication in the past 8 weeks made with the expectation of improving pain
  • No plan to start another medication or a non-pharmacologic treatment regimen likely to affect pain during the next 16 weeks
  • Age at least 18
  • Registered for medical care in the VA Boston Healthcare System
  • Capable of informed consent, and willingness to comply with study procedures, including receipt of weekly phone calls from the study coordinator

Exclusion Criteria:

Any of the following requires exclusion from participation:

  • Current use of opioids including tramadol
  • Pregnant, breast feeding, or unwilling to engage in contraceptive practices if sexually active and capable of conceiving
  • Schizophrenia, bipolar disorder, or poorly controlled depression or anxiety
  • Previous use of low-dose naltrexone
  • Back pain described by the patient as greater in severity than arthritic pain in a non-axial location
  • Significant kidney disease, defined as glomerular filtration rate < 30 ml/min
  • Liver cirrhosis. There is no specific screening procedure to exclude cirrhosis.
  • Painful peripheral neuropathy. There is no specific screening procedure.
  • Plan to have surgery during the next 16 weeks
  • Inconsistency in self-reporting at the screening visit. BPI, PainDETECT, WOMAC, and PROMIS-29 all contain 0-10 scales of average pain intensity, although the times listed vary from 1-4 weeks. The severity reported on these three scales cannot differ by more than 1.
  • Other qualitative circumstances that the investigator feels would make the patient a poor candidate for this clinical trial, such as an unstable social situation or unreliable transportation

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.